Phase 2 × Terminated × Other hematologic neoplasm × Clear all Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Phase 2 Terminated
15 enrolled 11 charts
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Phase 2 Terminated
1 enrolled 1 chart
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Phase 2 Terminated
53 enrolled 13 charts
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
Phase 2 Terminated
40 enrolled
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Phase 2 Terminated
235 enrolled
ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2 Terminated
5 enrolled 11 charts
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Phase 2 Terminated
5 enrolled
STIMULUS-AML1
Phase 2 Terminated
90 enrolled 26 charts
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Phase 2 Terminated
1 enrolled 8 charts
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
12 enrolled 10 charts
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Phase 2 Terminated
30 enrolled
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Phase 2 Terminated
8 enrolled 10 charts
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Phase 2 Terminated
20 enrolled
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
Phase 2 Terminated
2 enrolled 10 charts
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
Phase 2 Terminated
10 enrolled 9 charts
ARTEMIS
Phase 2 Terminated
92 enrolled
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Phase 2 Terminated
3 enrolled 10 charts
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase 2 Terminated
4 enrolled 7 charts
REGALIA
Phase 2 Terminated
9 enrolled
ACHIEVE
Phase 2 Terminated
16 enrolled
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
5
Phase 2 Terminated
10 enrolled
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
Phase 2 Terminated
10 enrolled 5 charts
PEMAZA
Phase 2 Terminated
26 enrolled
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Phase 2 Terminated
43 enrolled 14 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Terminated
30 enrolled
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
CLL1818
Phase 2 Terminated
5 enrolled
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 2 Terminated
66 enrolled 21 charts
Tocilizumab for Patients With Cancer and COVID-19 Disease
Phase 2 Terminated
1 enrolled 10 charts
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Phase 2 Terminated
25 enrolled
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Phase 2 Terminated
14 enrolled
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
Phase 2 Terminated
5 enrolled 9 charts
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Phase 2 Terminated
55 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Phase 2 Terminated
11 enrolled 15 charts
Study of Sequential CAR-T Cell Treating Leukemia Children
Phase 2 Terminated
81 enrolled
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Phase 2 Terminated
7 enrolled 12 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
Guadecitabine Extension Study
Phase 2 Terminated
35 enrolled 10 charts
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
46 enrolled
Pona-CELL
Phase 2 Terminated
4 enrolled